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Progestins stimulate respiration. We have previously shown prolonged ventilatory improvement in chronic
respiratory failure with short-term medroxyprogesterone acetate (MPA). The mechanism of the sustained
respiratory eect is unknown. Insulin-like growth factor-I (IGF-I) and insulin have anabolic eects which could
also improve ventilation in the long-term. To better understand the interactions between hormones and control of
breathing, we evaluated the degree and duration of changes in IGF-I, insulin and cortisol after short-term MPA
therapy in chronic respiratory insuciency.
Fourteen postmenopausal women with permanent or episodic hypercapnic or hypoxaemic respiratory failure
were recruited for a placebo-controlled single-blind trial. After 14 days of placebo treatment and 7 days of washout,
a daily dose of 60mg MPA was administered for 14 days. Serum IGF-I, insulin and cortisol were measured five
times at 3-week intervals: at baseline, after 14 days on placebo, after 14 days on MPA, and during the washout, on
days 21 and 42.
Serum IGF-I levels were 15?2 (SD 4?6), 20?8 (SD 6?8) and 17?2 (SD 6?4) at baseline, on MPA and after a 3-week
washout. Serum insulin levels did not change [12?5mU l71 (SD 4?1), 12?2mU l71 (SD 4?8) and 14?5mU l71 (SD 3?6),
respectively]. Serum cortisol did not change. On MPA, IGF-I increased on average by 5?6 nmol l71 [95%
confidence interval (95% CI) 1?4 to 9?9] or 42?0 % (95% CI 6?3 to 77?8) from baseline. The IGF-I response
coincided with the previously reported ventilatory improvement.
MPA 60mg daily for 2 weeks increases serum IGF-I in postmenopausal women with chronic respiratory
insuciency. During follow-up after MPA, there was a trend towards increased IGF-I and insulin levels. The role
of these two hormones to induce prolonged ventilatory stimulation could not be excluded and further studies in
larger populations are warranted.
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The incidence of sleep-disordered breathing (SDB) is higher
among men and postmenopausal women compared with
premenopausal women (1). Increasing occurrence of SDB
in postmenopausal women is most often attributed to
decline in progesterone concentration. However, many
other endocrine changes also occur during the menopause,
but their influence on SDB is not known. After menopause,
levels of serum insulin-like growth factor-I (IGF-I) decrease
faster than in premenopause. This appears not only to be
related to age but the menopause per se. Healthy womenReceived 14 February 2000 and accepted in revised form 10 April
2000.
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IGF-I levels than healthy age-matched premenopausal
women (2).
In severe sleep apnoea IGF-I level is decreased (3).
Increased level of IGF-I is associated with a higher
ventilatory sensitivity to carbon dioxide (CO2) (3). There
are also some data suggesting a possible direct eect of
insulin on respiratory control (4). MPA may increase IGF-I
(5) and insulin levels (6). Also the location of both IGF-I
and insulin receptors in parts of the brain associated with
both sensing of H+ ion concentrations (brain stem) and
integration of inputs from chemoreceptor areas (cerebel-
lum) suggests that these two hormones might be involved in
the control of breathing (7).
Progestins stimulate ventilation. Medroxyprogesterone
acetate (MPA) is regarded as a central chemoreceptor
stimulant (8), although there is also evidence for peripheral
action (9). According to our previous results in postmeno-
pausal women, MPA increases levels of waking blood gases# 2000 HARCOURT PUBLISHERS LTD
FIG. 1. Study design.
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The mechanism of the prolonged stimulatory eect of MPA
is unknown. The endocrine alterations after parenteral
MPA are known to subside slowly (11). Knowledge of
prolonged hormonal interactions of orally administered
MPA is limited to high doses (4100mg) administered
mainly as single daily doses.
MPA could be a suitable respiratory stimulant in
postmenopausal women with chronic respiratory failure
(10). MPA has also certain glucocorticoid properties.
Suppression in serum cortisol secretion occurs even with
daily doses of 100mg of MPA (12). However, unlike
glucocorticoids, MPA does not reduce growth rate in
children (11). Glucocorticoid-like eects are observed in up
to 30% of patients treated for longer than 6 weeks with
daily doses of the order of 1500mg MPA (13). Whether
daily doses of less than 100mg of MPA suppress serum
cortisol, is not known.
The sustained ventilatory eect on MPA that was
demonstrated in our previous study (10), led us to suspect
possible endocrine interactions. To better understand the
relations between hormones and breathing, we analysed the
frozen serum samples to evaluate the degree and duration
of changes in IGF-I and insulin in postmenopausal women
with chronic respiratory insuciency, induced by short-
term MPA therapy. Patients with chronic respiratory
failure often use corticosteroids, and therefore may have
adrenal suppression. To evaluate the safety of MPA in
terms of possible adrenal suppression, cortisol concentra-
tions were assessed also.
Methods
SUBJECTS
Fourteen postmenopausal women with permanent or
previous episodic hypercapnic or hypoxaemic respiratory
failure were enrolled in the trial. The respiratory failure was
due to chronic obstructive pulmonary disease (COPD),
end-stage asthma or late sequlae of pulmonary tuberculosis
and assessed with daytime arterial blood gas measurements.
Their mean age was 67?0 years (SD 6?30). The detailed
clinical characteristics of the subjects have been described
previously (10). The criteria for postmenopausal status
were age over 50 years, time since last menstruation at least
2 years and serum concentrations of follicle stimulating
hormone (FSH)430 IU l71. One subject on vaginal oestro-
gen therapy was allowed to continue with her hormone
replacement therapy.
The exclusion criteria were malignancies, heart diseases
(except cor pulmonale), hepatic, renal, psychiatric, and
neurological diseases, thromboembolic events, unstable
hypertension, severe rheumatoid arthritis, insulin depen-
dent diabetes, total serum cholesterol 49?5mmol l71,
serum triglycerides 42?5mmol l71, use of any alternative
medicine, medication with eects on the central nervous
system, progestins except for MPA given by the research
team, contraindications to MPA therapy, long-term oxygen
therapy, or current smoking. We also excluded patientswith abnormalities in white blood cell count, serum
creatinine, alanine aminotransferase, oestradiol, progester-
one, FSH, luteinizing hormone, prolactin, sex-hormone
binding globulin and TSH. Before the baseline visit,
patients were further evaluated by taking a medical-history
and physical examination.
Written informed consent was obtained from all patients.
The protocol was approved by the Joint Commission on
Ethics of Turku University and Turku University Central
Hospital and the National Agency for Medicines.
STUDY DESIGN
The 12-week study was a placebo-controlled single-blind
trial (Fig. 1). Seven days after the baseline visit the patients
started fortnight of placebo treatment. A 7-day placebo
washout period was then followed by MPA orally 30mg
b.i.d. for another fortnight. The follow-up was 6 weeks
after treatment. Patients were weighed and blood samples
for serum MPA, IGF-I, insulin and cortisol were collected
at 3-week intervals: at baseline, after 2 weeks on placebo,
after 2 weeks on MPA, and after a 3-week and a 6-week
washout period.
Thirty mg of oral MPA (Lutopolar1, Orion Pharma,
Espoo, Finland) was administered twice in the evening, at
21?00 hours and 23?00 hours, to achieve maximum plasma
concentrations and respiratory stimulation throughout the
night. Identical placebo tablets for the placebo treatment
were also provided by Orion Pharma, Finland. Compliance
was assessed by tablet counts, patient interviews and
measurements of serum MPA concentrations. Blood
samples for MPA, IGF-I, insulin and cortisol were
collected after an overnight fast in seated subjects at
08?00 hours at baseline, on the 14th day on placebo, on the
14th day on MPA, and after a 3-week and a 6-week
washout.
LABORATORY ASSAYS
IGF-I was determined with IRMA kit (Nichols Institute
Diagnostics, U.S.A.). Insulin was determined with Phade-
seph1 Insulin RIA kit (Pharmacia, Uppsala, Sweden).
Cortisol was determined with heterogeneous competitive
magnetic separation assay (Technicon Immuno-1 system,
U.S.A.). Serum MPA concentrations were determined by
liquid chromatography–tandem mass spectrometry (HP
1090 series II/L1 liquid chromatograph Hewlett-Packard,
Avondale, CA, U.S.A. and API III1 triple quadrupole
mass spectrometer, PE Sciex, Thornhill, Ontario, Canada).
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plasma. Metabolites of MPA were not measured.
STATISTICAL ANALYSES
The analyses were started with assessment of distribution
and variance. Serum cortisol was analysed with Friedman’s
w2-test, and further analysis with Wilcoxon Sign Rank test.
Weight, IGF-I and insulin were tested using the analysis of
variance for repeated measures, followed by contrasts based
on Fisher’s F-test with Bonferroni correction. Comparisons
between the first and the second sessions tested the placebo
eect, between the first and the third sessions the immediate
MPA eect and between the first and the fourth and the
first and the fifth the sustained eect of MPA. Confidence
intervals (CI) with Bonferroni corrections for the means of
the dierences were determined. In all tests, P50?05 was
considered significant. To identify possible correlations
between IGF-I level and previously reported PaCO2 and
PaO2 levels (10), Pearson correlation coecients were
calculated. Chi-square analysis was utilized to evaluate
the responder distributions. Statistical computing was
performed with SAS System for Windows, release 6?12/
1996 (SAS Inc., Cary, NC 1990).
Results
Thirteen out of 14 patients completed the trial. One subject
discontinued because of fever and viral respiratory tract
infection after her second visit. Other patients were
clinically stable. At baseline the mean BMI was
26?7 kgm72 (SD 5?22). Weight and BMI did not change
during the trial (Table 1). As earlier reported (10), range of
MPA while on treatment was 2?28–8?39 ngml71 (mean
4?33 ngml71). At the 3-week washout, MPA was under the
detection limit in three out of 13 subjects (23%). In the
remaining 10, the range of MPA was 0?032–0?196 ngml71
(mean 0?06 ngml71). At 6 weeks, MPA was undetectable in
all subjects.TABLE 1. Mean values (SD in parentheses) of serum IGF-I, ins
parentheses) of morning cortisol, n=13. MPA: medroxyprogest
MPA administration, washout (6wk): 6 weeks after the cessatio
insulin and weight) or Wilcoxon Sign Rank test (cortisol) with
Factor
(reference value)
Baseline Placebo P MPA
IGF-I
(5?0–28 nmol l71)
15?2
(4?6)
14?9
(4?7)
n.s.
(P=1?00)
20?8
(6?8)
Insulin
(5–20mU l71)
12?5
(4?1)
12?5
(3?9)
n.s.
(P=1?00)
12?2
(4?8) (
Cortisol
(150–650 nmol l71)
470
(219)
536
(91)
n.s.
(P=1?00)
454
(268) (
Weight (kg) 68?4
(14?5)
68?4
(14?4)
n.s.
(P=1?00)
68?0
(14?1) (MPA increased the mean IGF-I from 15?2 nmol l71 (SD
4?63) to 20?8 nmol l71 (SD 6?85). The average change was
5?6 nmol l71 (95% confidence interval (95% CI 1?4 to 9?9)
or 42?0% (95% CI 6?3 to 77?8). At the 3-week washout, the
average IGF-I was still 13?2 % above the baseline but the
dierence was not significant (95 % CI -2?5 to 28?9). At the
6-week washout IGF-I had returned to baseline (Fig. 2).
Changes in IGF-I levels did not correlate with simulta-
neously measured blood gas changes except at the 6-week
washout, when increase in IGF-I was related with decrease
in PaO2 (r=70?68, P=0?0097). In most subjects IGF-I and
PaO2 increased on MPA and remained increased at least 3
weeks after cessation of MPA (Table 2 and 3). PaCO2
decreased in most subjects on MPA and remained
decreased at 3 weeks after cessation of MPA (Table 3).
The dierences were evaluated with w2-tests knowing that
the test is not powerful with low n-values. None of the tests
was statistically significant. The long-term eects of the
acute MPA-induced IGF-I increase on blood gases during
the follow-up are demonstrated in Figs 3 and 4. At 3 weeks
after cessation of MPA, the majority of subjects still
remained responders in terms of blood gases, whereas at 6
weeks a random distribution was observed (Figs 3 and 4).
The mean serum insulin level was 12?5 mU71 (SD 4?1) at
baseline, 12?5mU l71 (SD 3?9) on placebo, 12?2mU l71 (SD
4?8) on MPA, 14?5mU l71 (SD 3?6) at the 3-week washout
and 14?2mU l71 (SD 4?4) at the 6-week washout (Table 1).
The percentage changes are shown in Fig. 2. The median
serum cortisol levels were 470 nmol l71 (interquartile
range, IQR 219), 536 nmol l71 (IQR 91), 454 nmol l71
(IQR 268), 508 nmol l71 (IQR 80), 568 nmol l71 (IQR
229), respectively (Table 1). No dierences observed in
insulin and cortisol were significant.
Discussion
EFFECTS OF MPA ON SERUM IGF-I
The present study shows that serum concentration of IGF-I
increases during MPA treatment in postmenopausalulin and weight, and median values (interquartile range in
erone acetate, washout (3wk): 3 weeks after the cessation of
n of MPA administration; P: Fisher’s F-test (serum IGF-1,
Bonferroni correction, n.s.: non-significant.
P Washout
(3 week)
P Washout
(6 week)
P
0?008 17?2
(6?4)
n.s.
(P=0?112)
15?5
(4?3)
n.s.
(P=1?00)
n.s.
P=1?00)
14?5
(3?6)
n.s.
(P=0?078)
14?2
(4?4)
n.s.
(P=0?725)
n.s.
P=1?00)
508
(80)
n.s.
(P=1?00)
568
(229)
n.s.
(P=0?230)
n.s.
P=1?00)
68?5
(14?7)
n.s.
(P=1?00)
68?5
(14?0)
n.s.
(P=1?00)
FIG. 2. IGF-I and insulin after a 14-day
medroxyprogesterone acetate (MPA) therapy. Values are
percentage changes from baseline on placebo, on MPA,
and after 3- and 6-week washouts. *=P5 0?05.
TABLE 2. Frequencies of changes in PaCO2 and serum IGF-I
during the study period. PaCO2: partial pressure of arterial
carbon dioxide, ; decrease in value; : increase in value; { no
change in value in one subject.
PaCO2; PaCO2:
IGF-I; IGF-I: IGF-I; IGF-I:
Placebo{
MPA
Washout (3 weeks)
Washout (6 weeks)
2
1
1
3
5
11
10
3
3
0
0
4
2
1
2
3
TABLE 3. Frequencies of changes in PaO2 and serum IGF-I
during the study period. PaO2: partial pressure of arterial
oxygen, ; decrease in value; : increase in value; { no change
in value in one subject.
PaO2; PaO2:
IGF-I; IGF-I: IGF-I; IGF-I:
Placebo{
MPA
Washout (3 weeks)
Washout (6 weeks)
2
0
1
3
4
2
4
5
3
1
0
4
3
10
8
1
FIG. 3. The MPA-induced increase in IGF-I and the acute
and long-term changes on PaCO2. MPA:
medroxyprogesterone acetate; PaCO2: partial pressure of
arterial carbon dioxide, 3 wk: a 3-week washout; 6 wk: a
6-week washout.
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cides with the decrease in PaCO2 and the increasing trend in
PaO2 [Tables 2 and 3 and Saaresranta et al. (10)]. The MPA
induced increase in IGF-I is in accordance with the earlier
observations that MPA increases plasma IGF-I levels both
in healthy women (5) and in women with advanced breast
cancer (14). Although IGF-I did not remain significantly
increased 3 weeks after cessation of MPA, the observedincreasing tendency in serum concentrations during the
washout period suggests that the MPA induced increase in
IGF-I was not short-lived.
Our results are also in line with the observations of
Malarkey et al. (15) in postmenopausal women. Combining
FIG. 4. The MPA-induced increase in IGF-1 and the acute
and long-term changes on PaO2. MPA:
medroxyprogesterone acetate; PaO2: partial pressure of
arterial oxygen, 3 wk: a 3-week washout; 6 wk: a 6-week
washout.
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observed decrease in serum IGF-I level was inhibited (15).
Contradictory to that, Bellantoni et al. (16) did not observe
a significant alteration of GH and IGF-I levels on MPA
treatment in healthy non-obese postmenopausal women.
MPA may increase IGF-I directly or indirectly through a
number of possible mediator hormones. The IGF-I increase
may also be secondary to altered environment including
improved ventilation, improved nutritional status or
improved sleep quality.
In physiological conditions, GH stimulates IGF-I secre-
tion. Most of the 24-h GH secretion occurs during the night
and the secretory pulses are sleep dependent. Contrary to
this, there is no circadian or sleep-related variation in the
serum IGF-I concentration (17). The proper assessment of
diurnal GH profile demands frequently repeated blood
samples. We decided not to measure the GH profiles, and
are therefore not able to evaluate the possible role of GH in
inducing the increase in IGF-I secretion. Sleep disturbances
are common in respiratory failure. With improved ventila-
tion, MPA could lead to improved sleep, proportion of
slow wave sleep, and amount of GH secreted during thatsleep stage. Increase in slow wave sleep (sleep stages 3 and
4) increases the secretion of pulsatile GH (18). However,
there is no evidence that MPA increases the amount of
slow-wave sleep (19). On the contrary, MPA is known to
suppress the sleep-induced peak in GH secretion (20).
Acromegalic patients with increased hypercapnic ventila-
tory response had lower etCO2 (end tidal CO2) levels and
higher IGF-I levels than those with decreased hypercapnic
ventilatory response (21). In transsexuals and male sex
oenders, MPA (400 mg i.m. weekly) caused an increase in
plasma IGF-I concentration but not in GH (22). This
suggests that MPA increases the IGF-I through other than
GH-mediated mechanisms.
Another explanation for increased IGF-I could be an
increase of plasma IGF-I binding proteins. IGF-I is bound
tightly to several binding proteins in plasma whereas only
less than 1% is free (23). Insulin-like growth factor binding
protein-3 (IGFBP-3), the most abundant IGFBP in the
circulation, is related in exponential fashion to serum IGF-I
levels (24). We measured the amount of total plasma IGF-I
concentrations by using the IRMA kit (Nichols Institute
Diagnostics, U.S.A.). In this method, the sample is acidified
to separate the IGF-I from IGFBPs. Thereafter excess
IGF-2 is added to the assay to block the IGFBP binding
sites from recombining with the released IGF-I. IGFBPs
were not measured and therefore their possible role cannot
be determined.
Nutritional status and dietary intake influence the IGF-I
levels (25). Our patients had normal weight. We did not
control diet during the 12-week study period, and the
subjects were allowed to maintain their habitual diets.
However, it is unlikely that change in nutritional status
would have increased the IGF-I levels because no weight
gain was observed and none of the patients reported a
change in appetite.
It cannot be excluded that the increase in IGF-I is
secondary to improved ventilation during MPA. Hyper-
capnia and hypoxaemia may suppress IGF-I secretion, and
the increase in IGF-I would result from a release of this
suppression. This is supported by the observations in
patients with sleep apnoea. The more severe the sleep
apnoea, the lower the IGF-I levels (26). Reversal of sleep
apnoea by nasal CPAP essentially restored the IGF-I levels
(26).
The impact of IGF-I on breathing is not well understood.
However, the simultaneous increases in progesterone, IGF-
I and ventilation, and decrease in PaCO2 are also observed
in conditions such as pregnancy (27,28) and the luteal phase
of the menstrual cycle (5,27) suggesting that a rise in IGF-I
is involved in increasing ventilation. Sleep-related hypox-
aemia in sleep apnoea results in alterations in metabolic
regulatory peptides, insulin, IGF-I and IGF-II in particular
(29). Chronic hypoxaemia in newborns is associated with a
decrease in IGF-I without any change in GH (30). Our
adult patients with respiratory failure had moderate
hypoxaemia, which tended to improve simultaneously with
the IGF-I increase on MPA (10).
Lung volumes decline with age. Aging is also related
to decreased lean body mass (31), basal and stimulated
GH secretion, basal IGF-I levels (32,33) and increased
914 T. SAARESRANTA ET AL.somatostatin level (34). GH seems to correlate with plasma
oestradiol levels. Basal and stimulated GH secretion are
greater in women than in men throughout the adulthood
until women achieve the menopause. In elderly women and
men, the eects of both gender and age on GH secretion
markedly diminish (32). Although GH has direct metabolic
eects on peripheral tissues, most of its growth-promoting
properties are mediated through the IGF family, especially
IGF-I. There is a greater decrease in IGF-I in healthy
postmenopausal women than in age-matched women who
still remain premenopausal (2).
In chronic respiratory insuciency, the respiratory
muscle pump often functions close to the limit of its
capacity to maintain eective ventilation. Increased load on
respiratory muscles causes muscle fatique which is deleter-
ious to muscle function. It is well established that GH
increases the expression of systemic IGF-I, as well as
autocrine/paracrine IGF-I in the skeletal muscle, and it is
believed that IGF-I is a major regulator of muscle growth
(35). IGF-I mediates most of the anabolic growth-promot-
ing eects of GH in muscle and skeletal muscle tissues (35,
36) and also in cultured fibroblasts derived from human
lung produce IGF-I (35). GH treatment increases ventila-
tion, central inspiratory drive, and CO2 response in children
with Prader–Willi syndrome (37). The authors suggest that
the improved ventilation might be attributed to an
improved inspiratory muscle performance. If the anabolic
eects of IGF-I induce improvement in ventilation by
strengthening the respiratory muscles and thereby giving
time for muscles to recover, the ventilation should remain
improved beyond the point when the eects of IGF-I are
subsiding.
EFFECTS OF MPA ON SERUM INSULIN
In our study, insulin levels tended to increase during
washout (Fig. 2) but, at least in this study population, the
increase did not reach statistical significance. IGF-I induces
hypolycaemia but also decreases insulin levels (38). The
increasing trend in insulin levels during the washout could
be a rebound eect. Insulin is an anabolic agent and might
possibly be involved in the previously observed prolonged
improvement of ventilation (10). The eects of MPA on
insulin are not consistent, since there has been no change
(39) or increase (6). In mice, diabetes reduced hypercapnic
ventilatory response during wakefulness and sleep. The
reduction was not related to plasma leptin levels and
obesity suggesting a possible direct eect of insulin on
ventilatory control (4).
EFFECTS OF MPA ON SERUM CORTISOL
Contradictory to most other studies with higher doses of
MPA (12,13), serum morning cortisol remained unchanged
in our patients. This suggests that MPA with a dosage
regimen of 60 mg in the evening for 2 weeks can be safely
administered without steroid-withdrawal symptoms in
postmenopausal women. Our finding may be explained by
at least two factors. Firstly, we used a lower dose comparedwith most other studies evaluating the suppressive eect of
MPA on cortisol. Secondly, MPA is usually divided into
three daily doses administered regularly throughout the
day. It is well established that glucocorticoids suppress
cortisol levels to a lesser extent when administered once
daily or on alternating days compared with multiple doses
throughout the day. We administered MPA divided into
two doses, both taken in the evening. This dosage regimen
could be one reason why cortisol suppression was not
observed. However, with a low n-value, exclusion of
cortisol suppression is done with a high risk for type II
error.
Conclusions
Impaired ventilation in aging women is often attributed to
a decrease in progesterone concentration. However, a
decrease in lung volumes or lean body mass, weakening
of respiratory muscle capacity probably due to decreased
IGF-I induced anabolic eects, and the alterations in
various other hormones are also likely to compromise
breathing in the elderly. Oestrogens modulate the proges-
terone action by regulating the progesterone receptors (40).
The increased release of somatostatin (34) suppresses
central respiratory drive (41) and reduces GH controlled
IGF-I production.
We conclude that MPA 60 mg daily for 2 weeks increases
serum IGF-I in postmenopausal women with chronic
respiratory insuciency. The pattern of IGF-I rise is
similar to previously reported ventilatory improvement
(10) which suggests that the IGF-I secretion and respiratory
stimulation are linked, either through a common controller
or through an interactive relationship. Insulin levels tended
to increase during washout but this observation needs
confirmation. Cortisol secretion was not altered suggesting
that MPA with this dosage regimen could safely be used
without glucocorticoid withdrawal symptoms.
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